Hepatitis C Triple Therapy Trial Begins with CTS-1027
Conatus Pharmaceuticals is optimistic that their developmental drug, CTS-1027, will give people with Hepatitis C a greater chance for beating the virus. In a Phase II Hepatitis C trial for previous non-responders, CTS-1027 is being paired with pegylated interferon and ribavirin.
Hepatitis C Is a Risk Factor for Heart Disease
February is American Heart Month. Since Hepatitis C has been proven to be a risk factor for coronary artery disease, the usual ways to reduce heart disease risk is insufficient for those with the virus. However, there are five strategies specifically for Hepatitis C that can reduce the likelihood of impending cardiac problems.
Ability to Study Hepatitis C Aided by New Model
By strategically interspersing liver cells and other specialized cells on growth plates, researchers have figured out how to grow Hepatitis C outside of the body - a critical tool to develop and test new Hepatitis C treatments.
More Hep C articles ... |